When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
REGN - Kodiak Sciences up 9% on positive early-stage KSI-301 data
Regeneron Pharmaceuticals Inc.
Kodiak Sciences (KOD+9%) announces encouraging results from a Phase 1b clinical trial evaluating KSI-301, an anti-VEGF antibody biopolymer conjugate with a potential dosing interval of three months or longer, in patients with treatment-naïve wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and retinal vein occlusion (RVO). The data were presented at the Angiogenesis, Exudation, and Degeneration Annual Meeting in Miami.
More news on: Kodiak Sciences Inc., Regeneron Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move,